person · Reporting owner

Cushman Elizabeth C.

Disclosed activity across 1 company

Tapewire entity: 14512
SEC CIK: 0002075371

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ABBOTT LABORATORIESABT · Entity 2314	EVP, GC AND SECRETARY	June 27, 2026	June 29, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ABBOTT LABORATORIES

Report date June 27, 2026 · Filed June 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common shares without par valueSEC Table I · non-derivative	Direct	38,013	Reported balance After 2026-06-27 transaction · row 1 1 source row Row 1 · 2026-06-27 · Tax withholding · Disposed 560 · Balance 38,013

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 27, 2026 Filed Jun 29, 2026 21:34 UTC	ABBOTT LABORATORIES ABT · Entity 2314	Tax withholdingCommon shares without par value	560	$94.12	$52,707.20	Disclosure SEC source: 0002075371-26-000009 · form4-06292026_090621.xml · nonDerivative · entry 1 Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,013 Read SEC document
March 02, 2026 Filed Mar 4, 2026 00:39 UTC	ABBOTT LABORATORIES ABT · Entity 2314	SaleCommon shares without par value	263	$115.58	$30,397.54	Disclosure SEC source: 0002075371-26-000007 · form4-03042026_120334.xml · nonDerivative · entry 2 Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,573 Read SEC document
February 27, 2026 Filed Mar 4, 2026 00:39 UTC	ABBOTT LABORATORIES ABT · Entity 2314	Tax withholdingCommon shares without par value	1,421	$116.26	$165,205.46	Disclosure SEC source: 0002075371-26-000007 · form4-03042026_120334.xml · nonDerivative · entry 1 Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,836 Read SEC document
February 24, 2026 Filed Feb 26, 2026 23:01 UTC	ABBOTT LABORATORIES ABT · Entity 2314	GrantOption (right to buy) · Derivative	61,964	$0.00 Strike: $114.60	$0.00	Disclosure SEC source: 0002075371-26-000002 · form4-02262026_110256.xml · derivative · entry 2 Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,964 Underlying: Common Shares · 61,964 shares Expires 2036-02-23 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,654 on February 24, 2027, 20,655 on February 24, 2028, and 20,655 on February 24, 2029. Read SEC document
February 24, 2026 Filed Feb 26, 2026 23:01 UTC	ABBOTT LABORATORIES ABT · Entity 2314	GrantCommon shares without par value	15,031	$0.00	$0.00	Disclosure SEC source: 0002075371-26-000002 · form4-02262026_110256.xml · nonDerivative · entry 1 Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,257 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document
June 27, 2025 Filed Jul 1, 2025 20:47 UTC	ABBOTT LABORATORIES ABT · Entity 2314	GrantOption (right to buy) · Derivative	14,680	$0.00 Strike: $133.90	$0.00	Disclosure SEC source: 0001415889-25-018721 · form4-07012025_080750.xml · derivative · entry 2 Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,680 Underlying: Common Shares · 14,680 shares Expires 2035-06-26 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,893 on June 27, 2026, 4,893 on June 27, 2027, and 4,894 on June 27, 2028. Read SEC document
June 27, 2025 Filed Jul 1, 2025 20:47 UTC	ABBOTT LABORATORIES ABT · Entity 2314	GrantCommon shares without par value	3,790	$0.00	$0.00	Disclosure SEC source: 0001415889-25-018721 · form4-07012025_080750.xml · nonDerivative · entry 1 Cushman Elizabeth C. · CIK 0002075371 · EVP, GC AND SECRETARY 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,226 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.